Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
NCT06342986Phase 1Active, not recruiting
- Sponsor
- Masonic Cancer Center
- Start
- Jul 2024
- Primary completion
- Mar 2026
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of FT536 in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (4 cohorts), sponsored by Masonic Cancer Center. Primary endpoint: Progression free survival at 1 year. Started Jul 2024; status: active, not recruiting.
02
Drugs
FT536
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT06342986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06342986.